Merck's Protease Inhibitor Franchise Growth Tied To MK-994A Combination
Executive Summary
Merck hopes to expand its HIV protease inhibitor franchise with a new combination formulation of Crixivan and MK-994, Merck Research Laboratories President Edward Scolnick, MD, said at a Dec. 9 analyst briefing in Whitehouse Station, N.J.
You may also be interested in...
Merck Maintains Merger-Free Philosophy; Co-Promotions Also Ruled Out
Merck will refrain from entering into co-promotion agreements to take advantage of its sales force capacity, CEO Raymond Gilmartin told securities analysts Dec. 9 at the company's Whitehouse Station, N.J. headquarters.
Merck Revenue Boost From Astra Deal Restructuring Is About $680 Mil.
Merck's restructuring of the Astra joint venture has boosted the company's revenue line by an amount roughly equivalent to the annual sales contribution from the ACE inhibitor Prinivil.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011